AGRX - Agile: Recent AdCom Decisions Further Support Twirla Approval
In a recent piece, I reviewed what I see as fundamentally undervalued equity shares of Agile Therapeutics ([[AGRX]]) and the Twirla patch's strong chances of approval in the context of the product's February 16 PDUFA date.
After this article was published, I dug into recent votes of the same FDA Advisory Committee and looked at what ultimately happened with FDA decision outcomes of the drug products reviewed. The discussion herein is meant to stimulate additional discussion around the BRUDAC's decisions; while all such regulatory cases are quite different, I believe this analysis offers additional